REVANESSE® ULTRA™ with Lidocaine Indications for Use
REVANESSE® ULTRA™ with Lidocaine is a hyaluronic acid-based injectable filler used to treat moderate to severe facial wrinkles, including nasolabial folds, and for lip augmentation. Its primary use is for restoring volume to areas affected by aging or lipoatrophy. The product helps correct contour deficiencies and provides aesthetic improvements by enhancing facial symmetry, fullness, and skin hydration.
- Cosmetic Applications: Used to fill deep wrinkles, restore volume, and enhance facial contours, including lips. It is suitable for both men and women desiring facial rejuvenation.
- Medical Applications: Effective in the treatment of volume loss caused by lipoatrophy (e.g., HIV-associated) and deformities resulting from trauma.
REVANESSE® ULTRA™ with Lidocaine Dosage Information
The product is supplied in a pre-filled syringe containing 1.2 ml of cross-linked hyaluronic acid at a concentration of 25 mg/ml, with an additional 0.3% lidocaine for pain relief during the injection. The correct dosage is determined based on the treatment area, patient needs, and depth of wrinkles. The average lifespan of the treatment is between 6-12 months, depending on the injection location and technique.
- Standard Dose: Each box contains two syringes, and the typical dose per session varies depending on the treatment area, with physicians using visual and tactile assessment to guide injection volumes.
- Administration: It is recommended to inject the product slowly and with minimal pressure. Only physicians or medical professionals trained in dermal filler techniques should administer this treatment.
REVANESSE® ULTRA™ with Lidocaine Side Effects and Precautions
Like all injectable treatments, REVANESSE® ULTRA™ with Lidocaine carries potential risks, which include common injection-related reactions and more serious adverse events. Patients must be informed of these risks before the procedure.
- Common Side Effects: These include temporary redness (erythema), swelling, tenderness, and mild bruising at the injection site, which generally resolve within one week.
- Rare but Serious Reactions: Glabellar necrosis, nodules, granulomas, abscess formation, and hypersensitivity reactions are reported in a small fraction of patients. These reactions are considered delayed hypersensitivity, occurring in less than 1 in every 1500 treatments. If symptoms persist beyond a week, patients must seek medical attention.
- Contraindications: The product is not suitable for individuals with allergies to lidocaine or hyaluronic acid. It should not be injected into areas with active inflammation, infection, or existing filler products, especially permanent fillers. Furthermore, the product is contraindicated in patients with autoimmune diseases, coagulation defects, or during pregnancy and breastfeeding.
Patients with a history of herpes simplex infections are at risk of reactivation after facial injections. In such cases, prophylactic treatment may be recommended. Furthermore, patients on anticoagulants or with coagulation defects should be evaluated carefully before receiving injections, as they have a higher risk of bleeding and bruising.
- Warnings: Intravascular injection may lead to serious complications like embolization, occlusion of blood vessels, ischemia, or even blindness. If symptoms such as sudden pain, vision changes, or blanching of the skin occur during the procedure, the injection must be halted immediately, and appropriate medical care sought.
REVANESSE® ULTRA™ with Lidocaine Clinical Studies and Real-World Outcomes
REVANESSE® ULTRA™ has been studied in various clinical settings, demonstrating efficacy in reducing deep wrinkles, restoring facial volume, and improving the skin’s appearance. Studies show high patient satisfaction, with results typically lasting up to 12 months. The inclusion of lidocaine in the formulation has improved patient comfort during the procedure, reducing pain levels significantly.
REVANESSE® ULTRA™ with Lidocaine Drug Interactions
The product should not be used alongside certain other treatments, such as laser therapies, chemical peels, or dermabrasion, due to the increased risk of adverse interactions. Additionally, medications that affect blood clotting, such as aspirin, non-steroidal anti-inflammatory drugs (NSAIDs), and certain supplements like Vitamin E, should be used cautiously as they can increase the risk of bruising at the injection site. Hyaluronic acid products like REVANESSE® ULTRA™ are also known to be incompatible with quaternary ammonium salts, such as benzalkonium chloride, which may cause adverse reactions.
REVANESSE® ULTRA™ with Lidocaine Administration and Injection Points
The product is injected intradermally or subcutaneously, depending on the area being treated. The injection sites must be disinfected thoroughly, and the product should be injected using sterile techniques. The manufacturer advises against touching the treated area for at least 12 hours post-injection and avoiding excessive sun exposure, extreme cold, and heat until initial swelling subsides. In case of blanching of the skin (an indication of potential vascular occlusion), the injection must be stopped immediately, and the area massaged to restore normal blood flow.
- Injection Sites: Common injection sites include the nasolabial folds, marionette lines, lips, and cheeks. Care should be taken when injecting near highly vascular areas such as the glabella and nose to avoid vascular embolization, which could result in serious complications such as blindness.
